ARCA biopharma Inc (ABIO)


Stock Price Forecast

Feb. 21, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading ARCA biopharma Inc chart...

About the Company

ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement for a single Phase 3 clinical trial. ARCA is also developing AB171, a thiol-substituted isosorbide mononitrate, as a potential genetically targeted treatment for heart failure and peripheral arterial disease.

Employees

13

CEO

Michael Bristow

Exchange

NASDAQ

Website

www.arcabiopharma.com

$M

Total Revenue

13

Employees

$34M

Market Capitalization

-1.91

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ABIO News

Arca Biopharma Board Approves Director Compensation Plan

28d ago, source: Hosted on MSN

On January 30, 2024, ARCA biopharma, Inc.’s Board approved compensation for its non-employee directors under its Director Compensation Policy. Each director received options to purchase 6,000 ...

ARCA biopharma Announces 2023 Financial Results

28d ago, source: Business Insider

WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted ...

ARCA biopharma Announces Third Quarter 2022 Financial Results

1mon ago, source: ADVFN

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported ...

ARCA biopharma, Inc.

8mon ago, source:

View ARCA biopharma, Inc. ABIO stock quote prices, financial information, real-time forecasts, and company news from CNN.

ARCA biopharma Announces 2023 Financial Results

2mon ago, source: Stockhouse

WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted ...

ARCA biopharma Inc ABIO

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ARCA biopharma, Inc.: ARCA biopharma Announces 2023 Financial Results

2mon ago, source: Finanznachrichten

Feb. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for ...

ARCA biopharma Inc ABIO

6d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

ARCA biopharma Inc

7d ago, source: U.S. News & World Report

A FINRA report shows investors of color are the fastest-growing group in the stock market, and they're coming in at a younger age. Sometimes it makes sense to sell a stock at a loss. Here's how to ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...